---
title: "SINOPHARM: Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263502594.md"
description: "SINOPHARM announced the performance of Sinopharm Accord for the first three quarters of 2025, with operating revenue of 55.124 billion yuan, a year-on-year decrease of 2.38%; net profit attributable to the parent company of 959 million yuan, a year-on-year decrease of 10.18%; and basic earnings per share of 1.72 yuan. In the third quarter of 2025, operating revenue was 18.328 billion yuan, a year-on-year decrease of 1.89%; net profit attributable to the parent company was 291 million yuan, a year-on-year decrease of 9.58%"
datetime: "2025-10-30T11:20:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263502594.md)
  - [en](https://longbridge.com/en/news/263502594.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263502594.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263502594.md) | [繁體中文](https://longbridge.com/zh-HK/news/263502594.md)


# SINOPHARM: Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%

According to the Zhitong Finance APP, SINOPHARM (01099) announced the performance of Sinopharm Accord for the first three quarters of 2025, achieving operating revenue of 55.124 billion yuan, a year-on-year decrease of 2.38%; the net profit attributable to shareholders of the listed company was 959 million yuan, a year-on-year decrease of 10.18%; basic earnings per share were 1.72 yuan. In the third quarter of 2025, the operating revenue was 18.328 billion yuan, a year-on-year decrease of 1.89%; the net profit attributable to shareholders of the listed company was 291 million yuan, a year-on-year decrease of 9.58%

### Related Stocks

- [Sinopharm Accord (000028.CN)](https://longbridge.com/en/quote/000028.CN.md)
- [SINOPHARM (01099.HK)](https://longbridge.com/en/quote/01099.HK.md)

## Related News & Research

- [Sinopharm Group's Nine-Month Profit Rises Despite Revenue Drop](https://longbridge.com/en/news/262800706.md)
- [Xprize founder Peter Diamandis launches new contest to manifest a new Star Trek](https://longbridge.com/en/news/278419951.md)
- [Sinopharm Group Reports Third Quarter 2025 Financial Results](https://longbridge.com/en/news/263504143.md)
- [Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership](https://longbridge.com/en/news/269631888.md)
- [Sinopharm’s CNMDC Reports Mixed Financial Results for 2025](https://longbridge.com/en/news/262387784.md)